Clinical trial register · Spain

Clinical Trials in Valencia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Valencia

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Córdoba

2024-07-24

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Barcelona, Cadiz, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Torrejón de Ardoz, Valencia

2024-07-19

Recruiting

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883Inflammatory Bowel Diseases, Crohn's Disease

DrugZotemtegrast

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Phase 2

385

Ferrol, Lleida, Madrid, Majadahonda, Seville, Valencia

2024-07-18

Recruiting

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580Generalized Myasthenia Gravis

DrugTelitacicept

Vor Biopharma

Phase 3

180

Alicante, Barcelona, Terrassa, Bilbao, Valencia

2024-07-17

Recruiting

The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer

NCT06643065Vaginal Microbiome

Fundación IVI

Observational

1,573

Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza

2024-07-17

Recruiting

Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)

NCT07111195Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Juan M Garcia-Gomez

Observational

140

Alicante, Barcelona, Murcia, Santa Cruz de Tenerife, Valencia

2024-07-16

Recruiting

Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy

NCT06474819Complete Heart Block, Second Degree Atrioventricular Block Möbitz Type II

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

326

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-07-12

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2024-07-09

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746Heart Failure

DrugsFinerenone·Dapagliflozin

Colorado Prevention Center

Phase 3

1,500

A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona

2024-07-09

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744Juvenile Psoriatic Arthritis

DrugsSkyrizi·Risankizumab·Adalimumab

AbbVie

Phase 3

Esplugues de Llobregat, Valencia

2024-07-08

Active, closed

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

NCT06248619Thyroid Eye Disease

DrugTeprotumumab

Amgen

Phase 3

Madrid, Seville, Valencia

2024-07-05

Active, closed

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT06526182Dermatitis, Atopic, Eczema

DrugLebrikizumab

Almirall, S.A.

Phase 3

520

Alicante, Barcelona, Granada, Valencia

2024-07-03

Recruiting

Transcranial Direct Current Stimulation on Functionality and Pain in Individuals With Patellar Tendinopathy

NCT06729437Patellar Tendinopathy

University of Valencia

Not applicable

Valencia

2024-07-01

By invitation

Validation of TAD in HER-2 with More Than 2 Lymph Nodes

NCT06821490Breast Carcinoma Metastatic in Lymph Node, HER2 Positive Breast Carcinoma

Fundación para la Investigación del Hospital Clínico de Valencia

Observational

Valencia

2024-06-30

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-06-28

Recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

NCT06459024Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Observational

4,000

Valencia

2024-06-28

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia

2024-06-28

Recruiting

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386Generalized Myasthenia Gravis

DrugEfgartigimod PH20

argenx

Phase 2/3

Valencia

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Sabadell, Santander, Manises, Madrid, Málaga, Valencia

2024-06-27

Recruiting

Colorectal Anastomosis Outcomes Using the Novel Powered Circular Stapler Compared With Manual Circular Staplers.

NCT06578065Colorectal Anastomosis

Fundación para la Investigación del Hospital Clínico de Valencia

Not applicable

540

Sabadell, Madrid, Murcia, Valencia

2024-06-27

Recruiting

BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

NCT06913712Idiopathic Intracranial Hypertension (IIH)

University of Valencia

Observational

Valencia

2024-06-27

Recruiting

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)

NCT06495970Pulmonary Hypertension

Gradient Denervation Technologies

Not applicable

Badalona, Barcelona, Valencia

2024-06-26

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Badalona, Córdoba, Oviedo, Barcelona, Valencia

2024-06-25

Active, closed

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

NCT06359002Relapsed / Refractory AML, Relapsed / Refractory MDS

Byondis B.V.

Phase 1

Badalona, Barcelona, Cáceres, Salamanca, Valencia

2024-06-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Barcelona, Madrid, Pamplona, Valencia

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

By invitation

Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1

NCT06131983Muscular Dystrophy, Facioscapulohumeral

Sarepta Therapeutics, Inc.

Phase 1/2

Barcelona, Madrid, Valencia

2024-06-19

Recruiting

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer

Oncoinvent Solutions AS

Phase 2

114

Barcelona, Madrid, Pamplona, Valencia

2024-06-15

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

200

Granada, Madrid, Valencia

2024-06-14

Recruiting

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

NCT06122584Prostate Cancer

Drug18F-PSMA-1007

ABX advanced biochemical compounds GmbH

Phase 3

380

Barcelona, Valencia

2024-06-13

Active, closed

Safety and Efficacy Of Amber Peripheral Liquid Embolic System

NCT06456125Vascular Anomalies, Hemorrhage, Aneurysm, Pseudoaneurysm

LVD Biotech S.L

Not applicable

Valencia

2024-06-12

Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

NCT06311682Atopic Dermatitis

DrugTralokinumab

LEO Pharma

Phase 3

195

Alicante, Madrid, Valencia

2024-06-10

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

A Coruña, Barcelona, Girona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2024-06-07

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Barcelona, Cáceres, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville, Valencia

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Active, closed

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

NCT06048718Breast Cancer, Metastatic Breast Cancer

DrugTrastuzumab deruxtecan

MedSIR

Phase 2

Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Barcelona, Córdoba, Madrid, Málaga, Valencia

2024-06-03

Recruiting

Personalised Health Recommendations to the General Population Through an Integrated AI Guided

NCT06421324Gastric Cancer, Cancer Prevention, Helicobacter Pylori Infection, Artificial Intelligence

Fundación para la Investigación del Hospital Clínico de Valencia

Not applicable

450

Valencia

2024-06-01

Active, closed

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 1/2

Seville, Madrid, Valencia

2024-05-30

Recruiting

Multimodal Program for Climacteric Women

NCT06419972Climacteric Syndrome, Postmenopausal Symptoms, Menopause, Perimenopausal Disorder

University of Valencia

Not applicable

115

Valencia

2024-05-30

Active, closed

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731Age Related Macular Degeneration (ARMD)

DrugElamipretide

Stealth BioTherapeutics Inc.

Phase 3

313

Barcelona, Valencia

2024-05-30

Active, closed

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification

DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab

Enliven Therapeutics

Phase 1

275

Barcelona, Madrid, Pamplona, Valencia

2024-05-30

Active, closed

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

NCT06422936Basal Cell Carcinoma

Highlight Therapeutics

Phase 2

Barcelona, Bilbao, Madrid, Salamanca, Valencia

2024-05-27

Recruiting

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315Mild Cognitive Impairment

Société des Produits Nestlé (SPN)

Not applicable

380

Alicante, Barcelona, Madrid, Salamanca, Sant Cugat del Vallès, Seville, Valencia

2024-05-24

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201Select Advanced Solid Tumors

CDR-Life AG

Phase 1

Barcelona, Madrid, Valencia

2024-05-24

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia

2024-05-21

Active, closed

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

NCT05735834Splenic Marginal Zone Lymphoma

DrugsTruxima·Zanubrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 3

122

Barcelona, Bilbao, El Palmar, Madrid, Pamplona, Salamanca, San Sebastián, Valencia

2024-05-21

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia

2024-05-21

Active, closed

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms

DrugsTucatinib·Disitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Barcelona, Bilbao, Erandio Bizkaia, Madrid, Valencia

2024-05-20

Recruiting

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin

Eli Lilly and Company

Phase 1

575

Barcelona, Madrid, Valencia

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Badalona, Ourense, León, Madrid, Salamanca, Valencia

2024-05-19

Active, closed

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302Diabetic Retinopathy

Boehringer Ingelheim

Phase 2

190

Barcelon, Madrid, Sant Cugat Del Vallés, Valencia

2024-05-15

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Santiago, Barcelona, Pamplona, Madrid, A Coruña, Valencia

2024-05-14

Recruiting

Proof of Concept, Randomized, and Crossover Study, to Assess the Effectiveness of Two Types of Compression Garments in Lipedema

NCT06964828Lipedema

Isabel Forner-Cordero, MD, PhD

Not applicable

Valencia

2024-05-08

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia

2024-04-29

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Barakaldo, Barcelona, Esplugues de Llobregat, Getafe, Valencia, Madrid

2024-04-22

Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia

DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 2

Badalona, El Palmar, Oviedo, Cáceres, Girona, Las Palmas de Gran Canaria, Salamanca, Valencia

2024-04-22

Active, closed

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935Crohn's Disease

DrugsTremfya·Guselkumab

Janssen-Cilag Ltd.

Phase 3

120

Alicante, Córdoba, Ferrol, Madrid, Valencia, Vigo

2024-04-17

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Alicante, Barcelona, Lleida, Madrid, Santiago de Compostela, Valencia

2024-04-16

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Córdoba, Seville

2024-04-14

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia

2024-04-12

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438Non-Small Cell Lung Cancer

DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

840

Santiago de Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2024-04-10

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia

2024-04-09

Recruiting

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

NCT06274515Breast Cancer

Hoffmann-La Roche

Phase 4

320

Madrid, Seville, Valencia

2024-04-02

Active, closed

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

NCT06200207Heart Failure, Systemic Inflammation

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

673

Castilleja de la Cuesta, Salamanca, Majadahonda, Madrid, Sanlúcar de Barrameda, Santiago de Compostela, Seville, Valencia

2024-04-01

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Barcelona, Madrid, Valencia

2024-04-01

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Barcelona, Madrid, Valencia

2024-03-28

Active, closed

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934Ulcerative Colitis

Gilead Sciences

Phase 2

228

Ferrol, Huelva, Santa Cruz de Tenerife, Seville, Valencia

2024-03-27

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672Polycythemia Vera

DrugHydroxyurea

Italfarmaco

Phase 3

220

Badalona, Alicante, Madrid, Málaga, Valencia

2024-03-26

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer

Iambic Therapeutics, Inc

Phase 1

383

Barcelona, Madrid, Málaga, Seville, Valencia

2024-03-25

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808HIV-1-infection

DrugsBictegravir·B/F/TAF·Lenacapavir

Gilead Sciences

Phase 3

577

Badalona Barcelona, Barcelona, Madrid, Seville, Valencia

2024-03-25

Recruiting

Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

NCT05914441Purpura, Thrombocytopenic

Fundación Española de Hematología y Hemoterapía

Observational

300

Seville, L'Hospitalet de Llobregat, Barcelona, Guadalajara, Madrid, Murcia, Valencia

2024-03-22

Active, closed

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386Asthma

DrugMepolizumab

GlaxoSmithKline

Phase 4

336

Barcelona, Girona, Valencia

2024-03-20

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

El Palmar, Donostia / San Sebastian, Barcelona, Córdoba, Madrid, Santiago de Compostela, Valencia

2024-03-18

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269Breast Cancer Stage IV

DrugSacituzumab Govitecan

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia

2024-03-15

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia

2024-03-14

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Córdoba, Sabadell, Valencia

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Córdoba, Sabadell, Valencia

2024-03-13

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia

2024-03-12

Active, closed

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

NCT06348199Non-small Cell Lung Cancer Stage IV

DrugsKeytruda·Pembrolizumab

Samsung Bioepis Co., Ltd.

Phase 3

555

Leganés, Málaga, Ourense, Oviedo, Santiago de Compostela, Seville, Valencia

2024-03-12

Recruiting

The NEU-STIM Trial

NCT05942924Infant, Premature, Diseases, Birth, Preterm

Leiden University Medical Center

Not applicable

3,280

Valencia

2024-03-11

Recruiting

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

NCT06353594ST Elevation Myocardial Infarction

Hospital Universitario La Fe

Not applicable

1,272

Huelva, Valencia, A Coruña, Burgos, Castelló, Córdoba, Elche, Granada

2024-03-11

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Cáceres, Córdoba, Madrid, Salamanca, Valencia

2024-03-07

Active, closed

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173Alzheimer Disease

Acumen Pharmaceuticals

Phase 2

542

Sant Cugat del Vallès, Cuarte de Huerva, Barcelona, Donostia / San Sebastian, Getxo, Madrid, Seville, Valencia

2024-02-29

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT05935215Atypical Hemolytic Uremic Syndrome

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia

2024-02-28

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Barcelona, Jaén, Madrid, Pamplona, Valencia

2024-02-27

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Barcelona, Madrid, Málaga, Seville, Valencia

2024-02-26

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar

DrugsXospata·Granulocyte Colony-Stimulating Factor·Ziftomenib·Idarubicin

Kura Oncology, Inc.

Phase 1

171

Barcelona, Oviedo, Seville, Valencia

2024-02-22

Recruiting

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

NCT06035120Emphysema, Pulmonary, Emphysema or COPD

Pulmonx Corporation

Not applicable

200

Valencia

2024-02-22

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza

2024-02-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

307

Badalona, Barcelona, Elche Alicante, La Laguna-Tenerife, Madrid, Marbella, Palma de Mallorca, Valencia

2024-02-21

Active, closed

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

NCT06185764Myotonic Dystrophy Type 1 (DM1)

DrugVX-670

Vertex Pharmaceuticals Incorporated

Phase 1/2

Valencia

2024-02-20

Recruiting

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

NCT05933057Duchenne Muscular Dystrophy

DrugHydroxyurea

Italfarmaco

Phase 3

138

Barcelona, Valencia

2024-02-19

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-02-17

Active, closed

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224B-Cell Non-Hodgkin Lymphoma (B-NHL)

DrugsOdronextamab·Ifosfamide·Paraplatin·Cytarabine

Regeneron Pharmaceuticals

Phase 3

216

Palma, Madrid, Pamplona, Valencia

2024-02-15

Active, closed

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500Small Cell Lung Carcinoma (SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 1

Madrid, Seville, Valencia

2024-02-14

Recruiting

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

NCT06078553Congenital Myasthenic Syndrome

argenx

Observational

100

Esplugues de Llobregat, Madrid, Valencia

2024-02-13

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia

2024-02-09

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Badalona, Terrassa, Barakaldo, Barcelona, Murcia, Girona, Valencia, Madrid

2024-02-08

Active, closed

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT06333483Systemic Lupus Erythematosus

DrugObecabtagene autoleucel

Autolus Limited

Phase 1

Barcelona, Valencia

2024-02-02

Active, closed

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

200

Santiago de Compostela, Málaga, Palma de Mallorca, Oviedo, Barcelona, Madrid, Seville, Valencia

2024-02-01

Active, closed

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT06150820Pompe Disease (Late-onset)

Astellas Gene Therapies

Not applicable

119

Albacete, Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Valencia

2024-02-01

Recruiting

Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation

NCT06280560Endometrial Receptivity

Fundación IVI

Observational

Valencia

2024-02-01

Recruiting

Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.

NCT06551285Polycystic Ovary Syndrome, Metabolic Syndrome

Celia Bañuls

Not applicable

120

Valencia

2024-02-01

Recruiting

Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication

NCT06049654Aortic Valve Stenosis, Structural Valve Deterioration

Fundación EPIC

Not applicable

104

L'Hospitalet de Llobregat, Madrid, Majadahonda, Salamanca, Valencia

2024-02-01

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Barcelona, Madrid, Pamplona, Valencia

2024-01-25

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Barcelona, Las Palmas de Gran Canaria, Madrid, Pamplona, San Sebastián, Santander, Santiago de Compostela, Valencia

2024-01-24

Active, closed

NEUROmuscular Training for Enhanced AGE Longevity

NCT06620666Aging, Physical Activity, Training

University of Valencia

Not applicable

390

Valencia

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia

2024-01-23

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

Barcelona, Madrid, Seville, Valencia, Málaga, Pozuelo de Alarcón

2024-01-23

Active, closed

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163Colitis, Ulcerative

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

112

Madrid, Sabadell, Valencia

2024-01-19

Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed

Revolution Medicines, Inc.

Phase 1/2

616

Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville

2024-01-18

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

774

Alicante, Barakaldo, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia

2024-01-17

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Alicante, Badalona, Barcelona, Cadiz, Madrid, Málaga, Santander, Valencia

2024-01-11

Recruiting

Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.

NCT06270199Bronchopulmonary Dysplasia

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 2

Pozuelo de Alarcón, A Coruña, Madrid, Málaga, Seville, Valencia

2024-01-11

By invitation

5-SENSE Score Validation Study

NCT06138808Epilepsy Intractable

Duke University

Observational

400

Valencia

2024-01-09

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263Acute Myeloid Leukemia

DrugsRVU120·Venetoclax

Ryvu Therapeutics SA

Phase 2

Barcelona, Cáceres, Madrid, Málaga, Pamplona, Seville, Valencia

2024-01-05

By invitation

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315Wheezing, Asthma

DrugDupilumab

Sanofi

Phase 3

Santiago de Compostela, Barcelona, Esplugues de Llobregat, Sabadell, Jerez de la Frontera, Madrid, Valencia

2024-01-03

Recruiting

Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study

NCT06336070Breast Cancer Female, Cardiometabolic Syndrome, Metabolism Disorder, Lipid, Autonomic Dysfunction

University of Valencia

Not applicable

Valencia

2024-01-01

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease

DrugsGedatolisib·Darolutamide

Celcuity Inc

Phase 1/2

Barcelona, Madrid, Valencia

2024-01-01

Recruiting

Evaluation of Improvements in Patient-reported Quality of Life

NCT06002022Breast Cancer, Quality of Life, Physical Activity, Sleep Quality

Fundación para la Investigación del Hospital Clínico de Valencia

Not applicable

110

Valencia

2024-01-01

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Jerez de la Frontera, Madrid, Ourense, Valencia, Lugo, Seville

2023-12-31

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Barcelona, Madrid, Salamanca, Valencia

2023-12-29

Active, closed

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337Persistent Atrial Fibrillation

Boston Scientific Corporation

Not applicable

484

Valencia

2023-12-28

Active, closed

Affera Global Registry

NCT06026345Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

540

Madrid, Valencia

2023-12-22

Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

NCT05280314Melanoma, Squamous Cell Carcinoma of Head and Neck

DrugsIO102-IO103·Pembrolizumab KEYTRUDA

IO Biotech

Phase 2

Barcelona, Madrid, Valencia

2023-12-21

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia

2023-12-21

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157Neoplasms

DrugsMomelotinib·Ruxolitinib

Janssen Research & Development, LLC

Phase 1

300

Badalona, Valencia

2023-12-20

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Barcelona, Palma de Mallorca, Santander, Valencia

2023-12-20

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Badalona, Getafe, Pozuelo de Alarcón, Granada, Madrid, Valencia, Zaragoza

2023-12-19

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Ávila, Granada, Madrid, Málaga, Valencia, Vigo

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Jerez de la Frontera, A Coruña, Pozuelo de Alarcón, Málaga, Valencia, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Badalona, Barcelona, Jaén, Madrid, Valencia

2023-12-14

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

Barcelona, Vigo, Valencia, Madrid, Oviedo, Seville

2023-12-13

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Barcelona, Esplugues de Llobregat, Oviedo, Seville, Málaga, Valencia, Vitoria-Gasteiz

2023-12-11

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Sabadell, Madrid, Pamplona, Barcelona, Seville, Valencia

2023-12-11

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Santiago, Granada, Barcelona, Alicante, Madrid, Valencia

2023-12-07

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Barcelona, Córdoba

2023-12-06

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

Barcelona, Santiago de Compostela, Seville, Valencia

2023-12-06

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Barcelona, Pamplona, Valencia

2023-12-05

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Sabadell, Santander, Majadahonda, Valencia, Barcelona, Madrid, Seville

2023-12-01

Active, closed

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786Carcinoma, Non-small-Cell Lung

DrugsJNJ-86974680·Cetrelimab

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

Barcelona, Madrid, Valencia

2023-11-27

Recruiting

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis

Alcyone Therapeutics, Inc

Not applicable

Madrid, Valencia

2023-11-27

Recruiting

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010Influenza

DrugBaloxavir Marboxil

Hoffmann-La Roche

Phase 3

1,100

Santiago de Compostela, Madrid, Valencia

2023-11-22

Recruiting

Cardioinhibitory Reflex Syncope. Permanent Pacemaker Therapy or Cardioneuroablation?

NCT05855603Reflex Syncope

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

Sant Joan d'Alacant, Castellon, Vigo, Barcelona, Girona, Santa Cruz de Tenerife, Valencia, Zaragoza

2023-11-22

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Barcelona, Córdoba, L'Hospitalet de Llobregat, Lugo, Madrid, Sabadell, Valencia

2023-11-21

Recruiting

Molecular Study of the Maternal-fetal Interface in Preeclampsia.

NCT06232668Preeclampsia

Carlos Simon Foundation

Observational

2,084

Alicante, Murcia, Santa Cruz de Tenerife, Valencia

2023-11-20

Active, closed

Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)

NCT06281392Inflammatory Bowel Diseases, Dysplasia

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Not applicable

122

Valencia

2023-11-15

Active, closed

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478Chronic Spontaneous Urticaria

DrugsOmalizumab·Remibrutinib

Novartis Pharmaceuticals

Phase 3

470

Granada, Barcelona, Córdoba, Las Palmas GC, Valencia

2023-11-15

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Barcelona, Madrid, Valencia

2023-11-14

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Barcelona, Jaén, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Santander, Valencia, Zaragoza

2023-11-14

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2023-11-14

Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617Multiple Myeloma

DrugsCevostamab·Iberdomide·Tocilizumab·Lenalidomide

Hoffmann-La Roche

Phase 1/2

200

Badalona, Madrid, Valencia

2023-11-14

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Madrid, Pamplona, Barcelona, Málaga, Murcia, Valencia

2023-11-13

Active, closed

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

NCT05784012Head and Neck Squamous Cell Carcinoma

DrugsNiraparib·Dostarlimab·Cisplatin

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia

2023-11-13

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413Unresectable Metastatic Colorectal Cancer

DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie

Phase 2

280

Barcelona, Madrid, Valencia, Zaragoza

2023-11-12

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Córdoba, Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Barcelona, Valencia, Zaragoza

2023-11-08

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

A Coruña, Barcelona, Madrid, Málaga, Valencia

2023-11-08

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Girona, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Seville, Valencia

2023-11-07

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

L'Hospitalet de Llobregat, Majadahonda, El Palmar, Madrid, Málaga, Seville, Valencia

2023-11-07

Active, closed

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565Hepatocellular Carcinoma

Boston Scientific Corporation

Phase 2

100

Barcelona, Pamplona, Oviedo, Madrid, Valencia, Valladolid

2023-11-03

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia

2023-11-02

By invitation

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

NCT06066580Becker Muscular Dystrophy

Edgewise Therapeutics, Inc.

Phase 2

260

Barcelona, Donostia / San Sebastian, Valencia

2023-11-02

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia

2023-10-31

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville, Valencia

2023-10-31

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms

Drugs177Lu-edotreotide·Everolimus

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

170

Seville, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Oviedo, Valencia, Barcelona

2023-10-27

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Badalona, Terrassa, Galdakao-Usansolo, Fuenlabrada, Madrid, Torrejón de Ardoz, Valencia

2023-10-25

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Barcelona, L'Hospitalet de Llobregat, Valencia, Granada, Madrid, Oviedo, Salamanca, Seville

2023-10-24

Active, closed

VOLT CE Mark Study

NCT06106594Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

Abbott Medical Devices

Not applicable

300

Valencia

2023-10-24

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Barcelona, Pamplona, Madrid, Santiago de Compostela, Valencia

2023-10-20

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Badalona, L'Hospitalet Del Llobregat, Barcelona, Pamplona, Madrid, Salamanca, Valencia

2023-10-16

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

DrugObrixtamig

Boehringer Ingelheim

Phase 2

204

Barcelona, Madrid, Málaga, Valencia

2023-10-13

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444Chronic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

759

Madrid, Málaga, Seville, Valencia

2023-10-12

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

311

Badalona, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Seville, Valencia

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

L'Hospitalet de Llobregat, Fuenlabrada, Barcelona, Córdoba, Madrid, Valencia

2023-10-11

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Santander, Barcelona, A Coruña, Majadahonda, Valencia

2023-10-10

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia

2023-10-10

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Ourense, Salamanca, Valencia

2023-10-05

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131Peripheral T Cell Lymphoma

DrugsBelinostat·Pralatrexate·CHOP·Prednisone

Acrotech Biopharma Inc.

Phase 3

504

Bilbao, Moncloa-Aravaca, Pamplona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2023-10-04

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402Multiple Myeloma

DrugElranatamab

Pfizer

Phase 4

Pamplona, Valencia

2023-10-03

Recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630Juvenile Idiopathic Arthritis

DrugsUpadacitinib·Tocilizumab

AbbVie

Phase 3

Esplugues de Llobregat, Valencia

2023-10-02

Recruiting

Post-Market Clinical Follow Up Study With Navitor Valve

NCT06008080Aortic Stenosis

Abbott Medical Devices

Observational

1,000

Badajoz, Barcelona, Huelva, Las Palmas, Majadahonda, Málaga, Valencia

2023-09-29

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

751

Barcelona, Madrid, Málaga, Valencia

2023-09-29

Recruiting

APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials

NCT06868355Cancer

University of Manchester

Observational

Barcelona, Madrid, Pamplona, Valencia

2023-09-28

Recruiting

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

NCT06114004Sarcoma,Soft Tissue

DrugsSelinexor·Gemcitabine

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

Phase 2

Santa Cruz de Tenerife, Barcelona, Donostia / San Sebastian, Madrid, Murcia, Valencia, Zaragoza

2023-09-28

By invitation

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

NCT05967351Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

400

Esplugues de Llobregat, Valencia

2023-09-27

Active, closed

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359Myeloproliferative Neoplasms

DrugsINCA033989·Ruxolitinib

Incyte Corporation

Phase 1

160

Madrid, Valencia

2023-09-25

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

A Coruña, Barcelona, Córdoba, Girona, Hospitalet deLlobregat, Madrid, Palma de Mallorca, Valencia

2023-09-22

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

A Coruña, Barcelona, Madrid, San Cristóbal de La Laguna, Seville, Valencia, Zaragoza

2023-09-21

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Santiago de Compostela, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Seville, Valencia

2023-09-18

Recruiting

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

NCT07309094Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2

DrugsExenatide·Canagliflozin·Liraglutide·Dulaglutide

Cardenal Herrera University

Observational

250

Valencia

2023-09-15

Active, closed

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886Hepatocellular Carcinoma

DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

687

Navarra, Pamplona/iruña, Oviedo, Barcelona, Jaén, Madrid, Valencia

2023-09-14

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Barcelona, Bilbao, Granada, Madrid, Seville, Valencia, VigoPontevedra

2023-09-13

By invitation

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis

DrugEfgartigimod PH20

argenx

Phase 3

240

Barcelona, Madrid, Valencia

2023-09-12

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

A Coruña, Barcelona, Córdoba, Girona, Granada, Valencia

2023-09-01

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Badalona, Barcelona, Cáceres, Madrid, Santander, Seville, Valencia

2023-08-31

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Barcelona, Madrid, Majadahonda, Málaga, Pontevedra, Sabadell, Seville, Valencia

2023-08-31

Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal

AviadoBio Ltd

Phase 1/2

Barcelona, Valencia

2023-08-30

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,772

Badalona, Barcelona, Córdoba, Madrid, Sabadell, Santiago de Compostela, Seville, Valencia

2023-08-30

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Badalona, Barcelona, Esplugues de Llobregat (Barc), Madrid, Sabadell, Valencia, Villarreal

2023-08-24

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

L'Hospitalet de Llobregat, Sabadell, Majadahonda, Barcelona, Madrid, Valencia

2023-08-14

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615Hormone-refractory Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 1

437

Barcelona, Logroño, Madrid, Málaga, Pamplona, Valencia

2023-08-10

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic

DrugsNemtabrutinib·Venetoclax·Rituximab

Merck Sharp & Dohme LLC

Phase 3

735

L'Hospitalet Del Llobregat, Pozuelo de Alarcón, Valencia

2023-08-08

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312Advanced Solid Tumors

DrugsDocetaxel·Paclitaxel·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 1

290

Barcelona, Madrid, Pamplona, Valencia

2023-07-28

Active, closed

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004Pneumonia, Bacterial

Eagle Pharmaceuticals, Inc.

Phase 2

276

Barcelona, Madrid, Santiago de Compostela, Tarragona, Terrassa, Toledo, Valencia, Valladolid

2023-07-22

Recruiting

Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy Vs. Thromboaspiration.

NCT06051032Pulmonary Embolism and Thrombosis

Instituto de Investigacion Sanitaria La Fe

Not applicable

Valencia

2023-07-21

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Barcelona, Pozuelo de Alarcón, Madrid, Málaga, Valencia

2023-07-19

Active, closed

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430Hypertension

Mineralys Therapeutics Inc.

Phase 3

1,076

Badajoz, Córdoba, Granada, Valencia

2023-07-14

Active, closed

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

100

Esplugues, Valencia

2023-07-11

Recruiting

Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy.

NCT06384794Infertility, Male, Sperm Count, Low

Instituto Valenciano de Infertilidad, IVI VALENCIA

Not applicable

Madrid, Valencia

2023-06-29

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Elche, Lugo, Madrid, Málaga, Valencia

2023-06-28

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

Barcelona, Madrid, Valencia

2023-06-27

Active, closed

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

451

Alcobendas, Barcelona, Colmenar Viejo, Madrid, Santiago de Compostela, Seville, Valencia, Valladolid

2023-06-26

Active, closed

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752Ovarian Cancer

USWM CT, LLC

Phase 2

Barcelona, Madrid, Valencia

2023-06-26

Active, closed

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

DrugEnvudeucitinib

Alumis Inc

Phase 2

408

A Coruña, Alicante, Barcelona, Seville, Valencia

2023-06-26

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Barcelona, Cáceres, Las Palmas de Gran Canaria, Murcia, Oviedo, Valencia, Badalona, Madrid

2023-06-22

Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

NCT05701358Acute Myocardial Infarction, Coronary Artery Disease

Population Health Research Institute

Not applicable

5,100

Madrid, Seville, Valencia, Valladolid

2023-06-22

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

L'Hospitalet de Llobregat, Majadahonda, Manises, Barcelona, Granada, Madrid, Valencia

2023-06-21

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Badalona, Barcelona, Madrid, Seville, Valencia

2023-06-20

Recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

NCT05967143Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)

Sirtex Medical

Observational

845

Majadahonda, Madrid, Valencia

2023-06-19

Recruiting

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621Propionic Acidemia

ModernaTX, Inc.

Observational

Esplugues de Llobregat, Santander, Barakaldo, Madrid, Seville, Valencia

2023-06-16

Active, closed

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

NCT05673187NSCLC Stage IV, KRAS P.G12C

DrugAdagrasib

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valencia

2023-06-12

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320Episodic Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

315

Vigo, Barcelona, Madrid, Valencia

2023-06-08

By invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949Migraine Prophylaxis

DrugAtogepant

AbbVie

Phase 3

650

Barcelona, Madrid, Seville, Valencia

2023-06-05

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT05908409Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified

DrugIDP-121

IDP Discovery Pharma S.L.

Phase 1/2

Santander, Salamanca, Barcelona, Madrid, Murcia, Seville, Valencia, Zaragoza

2023-06-05

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Málaga, A Coruña, Barcelona, Madrid, Valencia

2023-06-01

Active, closed

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

148

Esplugues de Llobregat, Valencia

2023-05-31

Active, closed

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis

DrugPegcetacoplan

Apellis Pharmaceuticals, Inc.

Phase 3

100

Barcelona, Madrid, Valencia

2023-05-29

Active, closed

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

NCT05809830Advanced Soft-tissue Sarcoma

DrugsDoxorrubicin·LB-100·Doxorubicin

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2

152

Barcelona, Madrid, Murcia, Valencia

2023-05-29

Active, closed

GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

NCT05674422Patients With Locally Advanced Rectal Cancer

Grupo Espanol Multidisciplinario del Cancer Digestivo

Observational

120

Badalona, Terrassa, Madrid, Barcelona, Girona, Valencia, Zaragoza

2023-05-26

Active, closed

Study of PYX-106 in Solid Tumors

NCT05718557Solid Tumor

Pyxis Oncology, Inc

Phase 1

Barcelona, Madrid, Valencia

2023-05-23

Recruiting

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

NCT06923761Advanced Solid Malignancy

Grey Wolf Therapeutics

Phase 1/2

300

Barcelona, Madrid, Málaga, Pamplona, Valencia

2023-05-21

Active, closed

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734Carcinoma, Non-Small-Cell Lung

DrugsCetrelimab·Amivantamab

Janssen Research & Development, LLC

Phase 1/2

Alicante, Barcelona, Madrid, Seville, Valencia

2023-05-18

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Santiago de Compostela, Barcelona, Esplugues de Llobregat, Madrid, El Palmar, Seville, Valencia

2023-05-17

Recruiting

Acute Pain Oscillation in Electroencephalographic Monitoring Under General Anaesthesia

NCT05873894Pain

Hospital General Universitario de Valencia

Observational

Valencia

2023-05-15

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

DrugTemozolomide

Debiopharm International SA

Phase 1/2

116

Barcelona, Donostia / San Sebastian, Madrid, Pamplona, Valencia

2023-05-15

Active, closed

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer

DrugTislelizumab

HiFiBiO Therapeutics

Phase 1

Madrid, Pamplona, Valencia

2023-05-09

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394Episodic Migraine

DrugAtogepant

AbbVie

Phase 3

450

Barcelona, Madrid, Seville, Valencia

2023-05-01

Active, closed

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

NCT06459648Migraine

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Observational

350

Zaragoza, Donostia / San Sebastian, Santander, Valladolid, Barcelona, Madrid, Valencia

2023-04-26

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Barakaldo, Barcelona, Madrid, Málaga, Valencia, Valladolid

2023-04-25

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Córdoba, Barcelona, Madrid, Seville, Valencia

2023-04-21

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia

2023-04-21

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Majadahonda, Pozuelo de Alarcón, Barcelona, Málaga, Seville, Valencia

2023-04-19

Recruiting

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

NCT05769868Cirrhosis, Diabetes Mellitus, Oncologic Disorders

DrugEsmolol

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Phase 3

1,000

Barcelona, Madrid, Salamanca, Valencia

2023-04-18

Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation

DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel

Institut de Recherches Internationales Servier

Phase 1/2

554

Barcelona, Madrid, Pamplona, Valencia

2023-04-18

Active, closed

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA

DrugApitegromab

Scholar Rock, Inc.

Phase 3

238

Barcelona, Valencia

2023-04-17

Active, closed

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

NCT07304843Primary Biliary Cholangitis (PBC)

Umecrine Cognition AB

Phase 1/2

202

Barcelona, Madrid, Málaga, Pontevedra, Santander, Seville, Valencia

2023-04-14

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589Neurotrophic Keratopathy

ReGenTree, LLC

Phase 3

Barcelona, Córdoba, Oviedo, Valencia

2023-04-11

Recruiting

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

NCT05890716Cardiomyopathies, Cardiac Arrest, Cardiac Arrhythmias, Sudden Cardiac Death

Idoven 1903 S.L.

Observational

5,342

Barcelona, Ciudad Real, A Coruña, Madrid, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia

2023-04-04

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

Barcelona, Granada, Madrid, Santander, Valencia

2023-04-03

Active, closed

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2

999

Badalona, Sabadell, Alicante, Córdoba, Madrid, Valencia

2023-04-03

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia

2023-03-30

Active, closed

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

NCT05501873Atrial Fibrillation

Boston Scientific Corporation

Observational

1,173

Madrid, Pamplona, Valencia, Zaragoza

2023-03-24

Recruiting

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

NCT05767047Behçet's Disease, Juvenile Psoriatic Arthritis

DrugApremilast

Amgen

Phase 3

Valencia, Madrid

2023-03-23

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

NCT05646836Multiple Myeloma

DrugsCevostamab·Tocilizumab

Genentech, Inc.

Phase 1

Pamplona, Valencia

2023-03-21

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Lleida, Seville, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2023-03-20

Recruiting

Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

NCT05781217Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Phase 3

534

L'Hospitalet de Llobregat, Fuenlabrada, Pozuelo de Alarcón, Barakaldo, Barcelona, Madrid, Tarragona, Valencia

2023-03-14

Recruiting

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117Solid Tumor, Advanced Solid Tumor

DrugPYX-201

Pyxis Oncology, Inc

Phase 1

330

Barcelona, Madrid, Valencia

2023-03-14

Recruiting

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT06511648Muscle-invasive Bladder Cancer

DrugErdafitinib

Spanish Oncology Genito-Urinary Group

Phase 2

Barcelona, A Coruña, Lugo, Madrid, Toledo, Valencia, Valladolid, Zaragoza

2023-03-07

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2023-03-06

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

A Coruña, Barcelona, Donostia / San Sebastian, Jaén, Madrid, Valencia, Badalona, Las Palmas de Gran Canaria

2023-03-06

Active, closed

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614Chemotherapy-induced Peripheral Neuropathy

AlgoTherapeutix

Phase 2

276

Barcelona, Córdoba, Jaén, Madrid, Reus, Valencia

2023-02-28

Recruiting

The Safety and Feasibility of the eLym™ System

NCT05747196Heart; Decompensation, Congestive

WhiteSwell, Limited

Not applicable

Barcelona, Badalona, Madrid, Majadahonda, San Carlos, Valencia, Valladolid

2023-02-28

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Badalona, Barcelona, Bilbao (Bizkaia), Madrid, Valencia

2023-02-27

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Barakaldo, Barcelona, Madrid, Seville, Valencia

2023-02-27

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

NCT05471856Solid Tumors

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

Barcelona, Madrid, Valencia

2023-02-24

Active, closed

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

NCT05469360Alzheimer Disease, Mild Cognitive Impairment

Novartis Pharmaceuticals

Phase 1

Valencia, Barcelona

2023-02-23

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

Santiago de Compostela, Barcelona, Madrid, Seville, Valencia

2023-02-21

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Barcelona, Las Palmas de Gran Canaria, Lugo, Málaga, Seville, Valencia

2023-02-21

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418HR+/HER2-negative Breast Cancer

DrugsRibociclib·Palbociclib·Fulvestrant

Totus Medicines

Phase 1

241

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2023-02-15

Active, closed

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899High-risk Large B-cell Lymphoma (LBCL)

DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin

Kite, A Gilead Company

Phase 3

300

Barcelona, Madrid, Salamanca, Santander, Seville, Valencia

2023-02-10

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Madrid, El Palmar, Pamplona, Valencia

2023-02-08

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Barakaldo, Badajoz, Barcelona, Burgos, Madrid, Seville, Valencia

2023-02-03

Recruiting

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

NCT05209243Prostate Cancer, Stereotactic Body Radiation Therapy

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Not applicable

266

Madrid, Valencia

2023-01-26

Active, closed

Registry on Percutaneous Electrochemotherapy

NCT05267080Primary Liver Cancer, Secondary Liver Cancer

Cardiovascular and Interventional Radiological Society of Europe

Observational

250

Valencia

2023-01-25

Recruiting

Impact of Serum Progesterone Levels on the Day of β-hCG Test in Artificial Cycles on the Ongoing Pregnancy Rate.

NCT05750849Infertility, Female

Instituto Valenciano de Infertilidad, IVI VALENCIA

Observational

900

Valencia

2023-01-25

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

A Coruña, Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Valencia

2023-01-24

Active, closed

Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant

NCT05186857Graft-versus-host Disease

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Observational

Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia

2023-01-23

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Valencia

2023-01-23

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Madrid, Valencia, Barcelona

2023-01-19

Active, closed

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361Multifocal Motor Neuropathy (MMN)

DrugEmpasiprubart

argenx

Phase 2

Barcelona, Valencia

2023-01-18

Active, closed

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

513

Mérida, Barcelona, Bilbao, Santander, Cordoba, Seville, Valencia, Valladolid

2023-01-12

Active, closed

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013Crohn Disease, Colitis, Ulcerative

DrugDuvakitug

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

247

Huelva, Santiago de Compostela, Valencia

2023-01-11

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Badalona, Córdoba, Barcelona, Madrid, Valencia

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Badalona, Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, San Cristóbal de La Laguna, Valencia, Granada

2023-01-10

Recruiting

Alleviant ALLAY-HF Study

NCT05685303Heart Failure

Alleviant Medical, Inc.

Not applicable

700

Barcelona, Cadiz, Madrid, Salamanca, Valencia

2023-01-10

Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm

DrugSTAR0602

Marengo Therapeutics, Inc.

Phase 1/2

366

Barcelona, Madrid, Valencia

2023-01-04

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Barcelona, Valencia, Bilbao, Córdoba, Granada, Madrid, Málaga

2022-12-29

Active, closed

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642Chronic Obstructive Pulmonary Disease (COPD)

DrugAstegolimab

Hoffmann-La Roche

Phase 3

1,290

Palma de Mallorca, Ponferrada, Torrejón de Ardoz, Benalmádena Costa, Barcelona, Seville, Valencia

2022-12-29

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Las Palmas de Gran Canaria, Lugo, Madrid, Santander, Seville, Valencia, Zaragoza

2022-12-29

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

NCT04953910Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugDecitabine

Taiho Oncology, Inc.

Phase 1

Barcelona, La Rioja, Lleida, Madrid, Murcia, Valencia

2022-12-23

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Barcelona, Huelva, Madrid, Pamplona, Salamanca, San Sebastián, Seville, Valencia

2022-12-23

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Barcelona, Madrid, Málaga, Valencia

2022-12-19

Active, closed

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

NCT05527340Multiple Myeloma

DrugsIberdomide·Daratumumab·Dexamethasone

PETHEMA Foundation

Phase 2

140

Madrid, Palma de Mallorca, Pamplona, Salamanca, San Cristóbal de La Laguna, Santander, Seville, Valencia

2022-12-15

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Barcelona, Madrid, Seville, Valencia

2022-12-15

Active, closed

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737Myelodysplastic Syndromes

DrugAzacitidine

Bristol-Myers Squibb

Phase 2/3

230

Valencia, Granada, Madrid, Ourense, Oviedo, Salamanca

2022-12-14

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Barcelona, A Coruña, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia

2022-12-13

Recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229Primary Mitochondrial Disease

DrugNapazimone

Pharming Technologies B.V.

Phase 2

180

Barcelona, Madrid, Valencia

2022-12-13

Active, closed

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314Carcinoma, Non-Small-Cell Lung

DrugsCapmatinib·Amivantamab

Janssen Research & Development, LLC

Phase 1/2

A Coruña, Alicante, Barcelona, Madrid, Seville, Valencia

2022-12-13

Active, closed

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT05529316Advanced Melanoma

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

150

Barcelona, Donostia / San Sebastian, Madrid, Seville, Valencia

2022-12-12

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Barcelona, Alicante, Las Palmas GC, Madrid, Valencia

2022-12-09

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Barcelona, Madrid, Seville, Valencia

2022-12-05

Recruiting

The Impact of Radiotherapy on Oligometastatic Cancer

NCT05933876Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer

Institut Investigacio Sanitaria Pere Virgili

Observational

2,000

Albacete, Barcelona, Granada, Lleida, Madrid, Seville, Reus, Valencia

2022-12-01

Recruiting

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

NCT05522660Non-Small Cell Lung Cancer, Melanoma

ETOP IBCSG Partners Foundation

Phase 3

180

Barcelona, Majadahonda, Valencia

2022-11-30

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia

2022-11-28

Active, closed

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

NCT05331183Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

297

Barakaldo, Barcelona, Jerez de la Frontera, Madrid, Murcia, Sabadell, Seville, Valencia

2022-11-23

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Barcelona, Madrid, Málaga, Valencia

2022-11-15

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

A Coruña, Alicante, Barcelona, Madrid, Málaga, Seville, Valencia

2022-11-11

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Barcelona, Madrid, Murcia, Sabadell, Seville, Valencia

2022-11-08

Active, closed

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure

DrugDapagliflozin

University Medical Center Groningen

Phase 3

1,750

Barcelona, Lleida, Madrid, Palma de Mallorca, Pamplona, Valencia

2022-11-08

Active, closed

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299End-stage Renal Disease

Xeltis

Not applicable

120

Barcelona, Valencia

2022-11-04

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga

2022-10-27

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515Non-Hodgkin Lymphoma

DrugsGolcadomide·Iberdomide·Mosunetuzumab·Glofitamab

Hoffmann-La Roche

Phase 1

121

L'Hospitalet de Llobregat, Valencia, Barcelona, Madrid, Salamanca

2022-10-26

Active, closed

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

NCT05387525Keratosis, Actinic

DrugDiclofenac Sodium

Almirall, S.A.

Phase 4

447

Barcelona, Granada, Madrid, Salamanca, Seville, Valencia, Zaragoza

2022-10-24

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma

DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab

Genentech, Inc.

Phase 1

165

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2022-10-20

Active, closed

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

NCT05620134Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer

DrugsLenvatinib Pill·Pembrolizumab

Salubris Biotherapeutics Inc

Phase 1/2

263

Barcelona, Madrid, Valencia

2022-10-17

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia

2022-10-14

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Santiago de Compostela, Aravaca, Barcelona, Granada, Madrid, Seville, Valencia

2022-10-14

Active, closed

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

NCT05046717Acquired Thrombotic Thrombocytopenic Purpura

Fundación Española de Hematología y Hemoterapía

Observational

500

A Coruña, Barcelona, Madrid, Valencia

2022-10-13

Active, closed

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases

DrugDonanemab

Eli Lilly and Company

Phase 3

1,500

Barcelona, Lleida, Sant Cugat del Vallès, Valencia

2022-10-10

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia

2022-10-04

Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

NCT05183035Acute Myeloid Leukemia

DrugsGemtuzumab Ozogamicin·Cytarabine·Azacitidine·Fludarabine

PedAL BCU, LLC

Phase 3

130

Barcelona, Madrid, Valencia

2022-10-01

Recruiting

Keeping RAASi Treatment With Optimal Potassium Control

NCT06578533Chronic Kidney Diseases

DrugSodium Zirconium Cyclosilicate

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 3

Alicante, Barcelona, Madrid, Valencia

2022-09-30

Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

NCT05476939Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered

DrugsDordaviprone·Everolimus

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

433

Barcelona, Madrid, Valencia

2022-09-29

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Barcelona, Madrid, Salamanca, Seville, Valencia

2022-09-22

Active, closed

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786Sarcoma, Ewing, Neoplasm Metastasis

DrugsAbemaciclib·Temozolomide·Irinotecan

Eli Lilly and Company

Phase 2

Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia

2022-09-20

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab

Exelixis

Phase 3

901

Barcelona, Lleida, Madrid, Valencia, Zaragoza

2022-09-07

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

109

Barcelona, Granada, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Valencia, Zaragoza

2022-09-06

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Córdoba, Madrid, El Palmar, Barcelona, Pamplona, Santiago de Compostela, Valencia

2022-08-31

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Barcelona, Madrid, Valencia

2022-08-29

Active, closed

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

DrugsPemetrexed·Carboplatin

iTeos Therapeutics

Phase 2

Palma de Mallorca, Pamplona, Valencia, A Coruña, Badajoz, Barcelona, Manresa, Ourense

2022-08-26

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Pamplona, Getxo, Barcelona, Córdoba, Lleida, Seville, Valencia

2022-08-24

Recruiting

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

NCT05156983Coagulation Disorder

Takeda

Phase 3

440

Salamnca, Valencia

2022-08-24

By invitation

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

NCT05374590Generalized Myasthenia Gravis, gMG

DrugsEfgartigimod PH20·Efgartigimod

argenx

Phase 2/3

Valencia

2022-08-18

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Santander, Vigo, Barcelona, Córdoba, Madrid, Valencia

2022-08-04

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

A Coruña, Barcelona, Córdoba, Madrid, Murcia, Valencia

2022-08-03

Active, closed

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

466

Barcelona, Madrid, Málaga, Pontevedra, Valencia, Zaragoza

2022-08-03

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Barcelona, Madrid, Valencia

2022-08-03

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595Advanced or Metastatic Colorectal Cancer

DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan

Janssen Research & Development, LLC

Phase 1/2

225

Barcelona, Madrid, Santander, Valencia

2022-07-29

Active, closed

Noninterventional Study Evaluating Parkinson's Disease Diary Use

NCT05363046Parkinson's Disease

BlueRock Therapeutics

Observational

194

Santurtzi, Barcelona, Pontevedra, Seville, Valencia

2022-07-29

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Murcia, Seville, Valencia

2022-07-20

Active, closed

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555Diffuse Large B Cell Lymphoma

DrugsTafasitamab·Lenalidomide

Incyte Corporation

Phase 1/2

Palma de Mallorca, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Seville, Valencia

2022-07-19

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid

2022-07-14

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Barcelona, Madrid, Seville, Valencia

2022-07-13

Active, closed

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446Metastatic Colorectal Cancer

DrugsEncorafenib·Erbitux·Cetuximab·Keytruda

Pfizer

Phase 2

108

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza

2022-07-11

Active, closed

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446Coronary Artery Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

610

A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2022-07-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA

DrugTaldefgrobep alfa

Biohaven Pharmaceuticals, Inc.

Phase 3

269

Donostia / San Sebastian, Esplugues de Llobregat, Málaga, Valencia

2022-07-06

Active, closed

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

529

A Coruña, Córdoba, Málaga, Santiago de Compostela, Seville, Valencia

2022-06-30

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Barcelona, Madrid, Valencia

2022-06-30

Recruiting

International Wilson's Disease Patient Registry (iWilson Registry)

NCT05239858Wilson's Disease

Orphalan

Observational

500

Las Palmas de Gran Canaria, Barcelona, Seville, Valencia

2022-06-29

Active, closed

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms

DrugsNab-paclitaxel /m^2·Relacorilant

Corcept Therapeutics

Phase 3

381

Badalona, San Sebastián, Valencia

2022-06-29

Active, closed

The Left Bundle Cardiac Resynchronization Therapy Trial

NCT05434962Left Bundle-Branch Block, Heart Failure, Impaired Left Ventricular Function

Óscar Cano Pérez

Not applicable

176

Alicante, L'Hospitalet de Llobregat, Granada, Huelva, Madrid, Majadahonda, Murcia, Valencia

2022-06-27

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Barcelona, Granada, Madrid, Santander, Valencia

2022-06-21

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189Non-Small Cell Lung Cancer

DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib

BioNTech SE

Phase 1

320

Badalona, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2022-06-17

Active, closed

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma

DrugsLoncastuximab Tesirine·Mosunetuzumab·Polatuzumab Vedotin·Glofitamab

ADC Therapeutics S.A.

Phase 1

154

Barcelona, Madrid, Salamanca, Valencia

2022-06-17

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia

2022-06-16

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2022-06-14

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

Pamplona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2022-06-08

Active, closed

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

NCT05115110Spinal Muscular Atrophy (SMA)

DrugsRO7204239·Risdiplam

Hoffmann-La Roche

Phase 2/3

Esplugues de Llobregas, Madrid, Valencia

2022-06-02

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

312

Barcelona, Leganés, Madrid, Moncloa-Aravaca, Pozuelo de Alarcón, Usera, Pamplona, Valencia

2022-05-25

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Barcelona, Las Palmas de Gran Canaria, Madrid, Toledo, Valencia

2022-05-22

Recruiting

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

DrugELA026

Electra Therapeutics Inc.

Phase 2/3

156

Madrid, Pamplona, Seville, Valencia

2022-05-19

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Seville, A Coruña, Barcelona, Madrid, Málaga, Oviedo, Pamplona, Valencia

2022-05-17

Active, closed

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257Limited-Stage Small Cell Lung Cancer

DrugsCarboplatin/cisplatin-etoposide·Serplulimab

Shanghai Henlius Biotech

Phase 3

511

Badajoz, Badalona, Barcelona, Córdoba, Madrid, Seville, Valdecilla, Valencia

2022-05-17

Recruiting

Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure

NCT05641662Cardiovascular Diseases

Linkoeping University

Not applicable

750

Barcelona, Manresa, Valencia

2022-05-16

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619Lupus Nephritis

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Mycophenolate Mofetil·Methylprednisolone

Hoffmann-La Roche

Phase 2

Esplugas de Llobregat, Madrid, Valencia

2022-05-12

Recruiting

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705Breast Cancer

DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 1

260

Barcelona, Madrid, Pozuelo de Alarcón, Valencia

2022-05-11

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Badalona, L'Hospitalet de Llobregat, El Palmar, Barcelona, Córdoba, Madrid, Málaga, Valencia

2022-05-02

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Pamplona, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2022-04-26

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

NCT04916613Prostate Cancer Metastatic

DrugDarolutamide

UNICANCER

Phase 3

300

Badalona, Barcelona, Girona, Madrid, Manresa, Valencia

2022-04-19

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Barcelona, Girona, Madrid, Marbella, Santiago de Compostela, Valencia

2022-04-19

Active, closed

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

NCT05201547Endometrial Cancer

DrugsCarboplatin/Paclitaxel·Dostarlimab

ARCAGY/ GINECO GROUP

Phase 3

260

Elche, Badalona, Córdoba, León, Palma, Palma de Mallorca, Santiago de Compostela, Valencia

2022-04-15

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Hospitalet, Madrid, Valencia, Badajoz, Seville

2022-04-14

Active, closed

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155Non-Muscle Invasive Bladder Neoplasms

DrugErdafitinib

Janssen Research & Development, LLC

Phase 1/2

235

Barcelona, Córdoba, Madrid, Valencia

2022-04-11

Active, closed

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Barcelona, Madrid, Valencia, Zaragoza

2022-04-01

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Barcelona, Madrid, Oviedo, Málaga, Valencia, Zaragoza

2022-03-29

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Ávila, Barcelona, Jaén, Madrid, Valencia

2022-03-25

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553Active Juvenile Psoriatic Arthritis

DrugApremilast

Amgen

Phase 3

San Cristóbal de La Laguna, Barcelona, Esplugues de Llobregat, Valencia, Madrid

2022-03-17

Active, closed

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease

Diagram B.V.

Not applicable

1,223

Barcelona, Madrid, Santander, Valencia

2022-03-16

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Girona, Madrid, Valencia, Barcelona, Lugo, Málaga

2022-03-15

Recruiting

High-intensity Functional Training on Functional and Cognitive Performance in People with Parkinson's Disease.

NCT06879821Parkinson Disease

Fundacion Para La Investigacion Hospital La Fe

Not applicable

Valencia

2022-03-14

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

A Coruña, Palma, Barcelona, El Palmar, Málaga, Pamplona, Reus, Valencia

2022-03-11

Active, closed

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma

DrugTislelizumab

HiFiBiO Therapeutics

Phase 1

Barcelona, Madrid, Valencia

2022-03-10

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Málaga, Palma de Mallorca, EI Palmar, Barcelona, Cáceres, Madrid, Valencia, La Laguna Tenerife

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza

2022-03-04

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398Migraine

DrugRimegepant

Pfizer

Phase 3

640

Sabadell, Valladolid, Vigo, Valencia, Madrid, Seville

2022-02-28

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Barcelona, Málaga, Valencia, Vigo, Zaragoza

2022-02-21

Active, closed

Clinical Impact of the IBox As an Early Intervention TooL

NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications

Predict4Health

Not applicable

507

Barcelona, Valencia

2022-02-18

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2

310

Barcelona, Madrid, Murcia, Valencia

2022-02-17

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2022-02-07

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2022-02-03

Active, closed

TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT04561986Antibody-mediated Rejection

DrugTocilizumab

Vastra Gotaland Region

Phase 3

A Coruña, Barcelona, Valencia

2022-02-01

Recruiting

Involvement of Muscle Mitochondrial Dysfunction in Frailty in Older Adults. Role of Exercise

NCT07828847Diabetes Type 2, Frail Elderly Syndrome, Mitochondrial Function, Bioenergetics, Functionality

Fundación para la Investigación del Hospital Clínico de Valencia

Not applicable

120

Valencia

2022-01-29

Active, closed

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628Trigeminal Neuralgia

Noema Pharma AG

Phase 2/3

166

Madrid, Seville, Valencia

2022-01-11

Active, closed

Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III

NCT07821333Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell

DrugsFolfoxiri·Folfox

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 2

L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Valencia

2022-01-01

Active, closed

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226Neuroendocrine Tumors

DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin

ITM Solucin GmbH

Phase 3

259

Barcelona, Madrid, Oviedo, Santiago de Compostela, Valencia

2021-12-21

Recruiting

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda

Phase 2

135

Badalona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2021-12-16

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugDecitabine

Taiho Oncology, Inc.

Phase 1

Barcelona, La Rioja, Lleida, Madrid, Murcia, Valencia

2021-12-15

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia

2021-12-14

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

Barcelona, Valencia

2021-12-14

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

HebrOn, León, Madrid, Santander, Valencia, Vigo

2021-12-14

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Barcelona, Valencia, Madrid

2021-12-08

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2021-12-07

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

Vigo, Barcelona, Madrid, Seville, Valencia

2021-12-01

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Málaga, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Valencia, Madrid

2021-12-01

Active, closed

Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II

NCT04893291Coronary Artery Disease, Coronary Artery Stenosis

Fondazione Ricerca e Innovazione Cardiovascolare ETS

Not applicable

1,820

Ciudad Real, Lugo, Madrid, Santander, Valencia, Vigo, Vitoria-Gasteiz

2021-11-16

Active, closed

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

NCT05039840Systemic Lupus Erythematosus

DrugFrexalimab

Sanofi

Phase 2

109

Sabadell, Madrid, Valencia, Valladolid

2021-11-10

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia

2021-11-02

Recruiting

Effectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function in People With Incomplete Spinal Cord Injury.

NCT05142943Incomplete Spinal Cord Injury, Spinal Cord Injury

University of Valencia

Not applicable

Valencia

2021-11-01

Recruiting

Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery

NCT04754022Disorder, Heart, Postoperative, Cardiac Surgery

Unity Health Toronto

Not applicable

1,440

Barcelona, Valencia

2021-11-01

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2021-10-28

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Guipuzcoa, Madrid, Murcia, Seville, Valencia

2021-10-27

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

Palma de Mallorca, Santiago de Compostela, Madrid, Majadahonda, Pamplona, Valencia

2021-10-27

Active, closed

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

GWT-TUD GmbH

Phase 3

Badalona, Barcelona, Madrid, Oviedo, Salamanca, Valencia

2021-10-27

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894Generalized Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 2/3

Esplugues de Llobregat, Valencia

2021-10-26

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

400

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-10-25

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Tecentriq

Hoffmann-La Roche

Phase 1

542

Donostia / San Sebastian, Majadahonda, Barcelona, Madrid, Valencia, Zaragoza

2021-10-22

Active, closed

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic

DrugUstekinumab

Janssen Research & Development, LLC

Phase 3

159

Valencia

2021-10-18

Active, closed

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence

DrugsOxaliplatine·Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2

Barcelona, Madrid, Santander, Valencia

2021-10-05

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville

2021-10-04

Recruiting

Creation and Validation of a Questionnaire Evaluating Diastasis Recti

NCT04158180Diastasis Recti and Weakness of the Linea Alba, Diastasis Recti

University of Valencia

Observational

125

Plasencia, Valencia

2021-09-27

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-09-23

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718ALK Fusion-positive Solid or CNS Tumors

DrugAlectinib

Hoffmann-La Roche

Phase 1/2

Madrid, Seville, Valencia

2021-09-14

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Barcelona, Madrid, Majadahonda, Valencia

2021-09-13

Recruiting

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

NCT04528082Behçet Disease

DrugApremilast

Amgen

Phase 3

Seville, Barcelona, Esplugues de Llobregat, Valencia, Madrid

2021-09-09

Active, closed

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811Non Small Cell Lung Cancer

DrugTaletrectinib

Nuvation Bio Inc.

Phase 2

217

Barcelona, Madrid, Málaga, Seville, Valencia

2021-09-01

Recruiting

Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases

NCT04616495Colorectal Cancer, Metastatic Liver Cancer, Liver Metastases

Hospital Universitario La Fe

Observational

Valencia

2021-09-01

Active, closed

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795Non-small Cell Lung Cancer Metastatic

Sophia Genetics SAS

Observational

4,000

Madrid, Valencia

2021-08-21

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

NCT04629833Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 3

210

Badalona, Barcelona, Madrid, Málaga, Valencia

2021-08-16

Active, closed

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975EPP, XLP

Tanabe Pharma America, Inc.

Phase 3

286

Barcelona, Madrid, Valencia

2021-08-10

Recruiting

European Disease Registry on Retinopathy of Prematurity (ROP)

NCT04939571Retinopathy of Prematurity

University Medicine Greifswald

Observational

3,000

Málaga, Valencia

2021-08-06

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma

Pierre Fabre Medicament

Phase 1

400

Barcelona, Madrid, Málaga, Seville, Valencia, Las Palmas de Gran Canaria

2021-08-04

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Badalona, Barcelona, Cartagena, Galdakao, Madrid, Seville, Valencia

2021-08-04

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Alicante, Barcelona, Bilbao, Seville, Valencia

2021-07-15

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189Psoriatic Arthritis

DrugsApremilast·Deucravacitinib

Bristol-Myers Squibb

Phase 3

729

Barcelona, Madrid, Santander, Valencia

2021-07-15

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Barcelona, Madrid, Santander, Seville, Valencia

2021-07-08

Active, closed

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2021-07-02

Active, closed

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

NCT04595266Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer

DrugsFolfox·Bevacizumab

Grupo Espanol Multidisciplinario del Cancer Digestivo

Phase 2

Barcelona, Sabadell, Madrid, Pamplona, Valencia

2021-06-29

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Barcelona, Cáceres, Córdoba, Granada, Madrid, Málaga, Santiago de Compostela, Valencia

2021-06-28

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Santander, Barcelona, Madrid, Málaga, Pamplona, Oviedo, Valencia

2021-06-25

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

DrugsSamuraciclib·Ipatasertib·Giredestrant·Phesgo

Hoffmann-La Roche

Phase 1/2

316

Barcelona, Madrid, Valencia

2021-06-22

Recruiting

Apomorphine in Severe Brain-injured Patients

NCT05213169Disorder of Consciousness

University of Liege

Phase 2/3

Valencia

2021-06-18

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Barcelona, Pozuelo de Alarcón, Madrid, Valencia

2021-06-18

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga

2021-06-15

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

L'Hospitalet de Llobregat, Sabadell, Majadahonda, El Palmar, Barcelona, Madrid, Valencia

2021-06-09

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-06-08

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

150

Córdoba, Esplugues de Llobregat, Sabadell, Valencia

2021-05-26

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Santander, Valladolid, Barcelona, Granada, Seville, Valencia

2021-05-25

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm

DrugsPosaconazole·Sonrotoclax·Azacitidine

BeOne Medicines

Phase 1/2

260

Barcelona, Salamanca, Seville, Valencia

2021-05-24

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Barcelona, Madrid, Pamplona, Santiago de Compostela, Valencia

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2021-05-19

Active, closed

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

DrugTofersen

Biogen

Phase 3

158

Valencia

2021-05-17

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Sabadell, Santander, Córdoba, Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia

2021-05-03

Active, closed

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

DrugsBispecific·Tagrisso·Osimertinib

Merus B.V.

Phase 1/2

194

Barcelona, Madrid, Pamplona, Valencia

2021-04-28

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Lenvatinib·Atezolizumab

Hoffmann-La Roche

Phase 3

557

Palma de Mallorca, Santiago de Compostela, Pamplona/iruña, Córdoba, Madrid, Valencia, Zaragoza

2021-04-26

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Badalona, Manresa, Girona, Santiago de Compostela, Las Palmas de Gran Canaria, Oviedo, Valencia, Barcelona

2021-04-21

Active, closed

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699Solid Tumor

DrugsIDE397·Sacituzumab Govitecan

IDEAYA Biosciences

Phase 1

169

Madrid, Valencia

2021-04-14

Active, closed

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis

DrugsIxekizumab·Adalimumab

Eli Lilly and Company

Phase 3

101

Esplugues de Llobregat, Madrid, Málaga, Seville, Valencia

2021-04-13

Recruiting

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

NCT04855435Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma

MonTa Biosciences ApS

Phase 1

106

Barcelona, Madrid, Valencia

2021-04-12

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Málaga, Barcelona, L'Hospitalet de Llobregat, Pamplona, Palma de Mallorca, Madrid, Valencia

2021-04-08

Active, closed

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Lenalidomide·Dexamethasone

PETHEMA Foundation

Phase 2

Palma de Mallorca, Santander, Salamanca, Santiago de Compostela, Madrid, Gijón, Valencia, Las Palmas de Gran Canaria

2021-04-07

Active, closed

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181Non-alcoholic Steatohepatitis

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,205

Pontevedra, Barcelona, Majadahonda, Santander, Seville, Valencia, Valladolid

2021-04-01

By invitation

Prehabilitation and Posttransplant Training Program in Liver Transplantation

NCT04246970Liver Transplant; Complications, Cirrhosis, Liver, Hepatic Carcinoma

Maria dels Angels Cebria i Iranzo, PT, PhD

Not applicable

Valencia

2021-04-01

Active, closed

Integrated Patient Care Intradialysis Programme in Hemodialysis Through a Virtual Health Platform

NCT04823286End Stage Renal Disease, Hemodialysis-Induced Symptom, Chronic Kidney Diseases

Cardenal Herrera University

Not applicable

Terrassa, Manises, Valencia

2021-03-31

Active, closed

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007Myelofibrosis

DrugsBMS-986158·Fedratinib·Ruxolitinib

Bristol-Myers Squibb

Phase 1/2

216

Badalona, Santander, Madrid, Salamanca, Valencia

2021-03-22

Active, closed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugFluzoparib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

496

Castellon, Barcelona, Córdoba, Girona, Madrid, Málaga, Seville, Valencia

2021-03-18

Active, closed

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 1/2

241

Sant Cugat del Vallès, Donostia / San Sebastian, Barcelona, Madrid, Valencia

2021-03-15

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Badalona, Madrid, Seville, Valencia

2021-03-09

Recruiting

Evaluation of Materials for the Distribution of Pressure in the Treatment of Neuroischemic Ulcers

NCT07620379Diabetic Complications, Foot Care

University of Valencia

Not applicable

Valencia

2021-03-09

Recruiting

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.

NCT04766866Preeclampsia, Intrauterine Growth Restriction, Maternal Hypertension, Neonatal Outcome

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

9,132

Badalona, Las Palmas de Gran Canaria, El Palmar, Barcelona, Madrid, Palma de Mallorca, Valencia, Zaragoza

2021-03-02

Recruiting

A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy

NCT07856329Duchene Muscular Dystrophy

Genethon

Phase 2/3

Esplugues de Llobregat, Valencia

2021-03-01

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-02-24

Active, closed

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689Small-Cell Lung Cancer

DrugsEtoposide·Durvalumab·Cisplatin·Carboplatin

AstraZeneca

Phase 2

Seville, Valencia

2021-02-23

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Barcelona, Madrid, Seville, Valencia

2021-02-23

Active, closed

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081Acute Myeloid Leukemia

DrugsDecitabine·Venclexta·Venetoclax

Taiho Oncology, Inc.

Phase 1/2

101

Oviedo, L'Hospitalet de Llobregat, Pamplona, Madrid, Salamanca, Valencia

2021-02-09

Active, closed

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

NCT04229979Acute Myeloid Leukemia

DrugsGm-Csf·Sargramostim·Ara-C·Decitabine

Sellas Life Sciences Group

Phase 3

127

Cáceres, Córdoba, Madrid, Oviedo, Pamplona, Salamanca, Seville, Valencia

2021-02-08

Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267Amyotrophic Lateral Sclerosis

DrugsMasitinib·Riluzole

AB Science

Phase 3

495

Alicante, Barcelona, Madrid, Santiago de Compostela, Valencia

2021-02-02

Active, closed

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

NCT04649359Multiple Myeloma

DrugElranatamab

Pfizer

Phase 2

187

Madrid, Valencia

2021-02-02

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Esplugues de Llobregas, Barcelona, Madrid, Valencia

2021-01-18

Active, closed

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms

DrugsTucatinib·Herceptin·Fulvestrant·Trastuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

217

L'Hospitalet de Llobregat, Barcelona, Valencia

2021-01-11

Active, closed

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

NCT04599946Dermatitis, Atopic, Eczema, Infantile, Infant Development, Child Development

Dairy Goat Co-operative (N.Z.) Limited

Not applicable

2,132

Almería, Granada, Madrid, Reus, Tarragona, Valencia, Zaragoza

2021-01-08

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Barcelona, Girona, Jaén, Madrid, Majadahonda, Málaga, Palma de Mallorca, Valencia

2021-01-07

Recruiting

Natural History of Clostridioides Difficile Infection

NCT04801862Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection

Hospital Universitario de Valme

Observational

750

Alicante, Orihuela, Villajoyosa, Puerto Real, Granada, Huelva, Málaga, Valencia

2021-01-01

Active, closed

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

NCT04735978Advanced Solid Tumor

DrugNivolumab

Replimune, Inc.

Phase 1

123

Barcelona, Madrid, Valencia

2020-12-29

Active, closed

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652Non-small Cell Lung Cancer

DrugsDato-DXd·Docetaxel

Daiichi Sankyo

Phase 3

605

Barcelona, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza

2020-12-21

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Barcelona, Madrid, Seville, Valencia, Zaragoza

2020-12-21

Active, closed

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT04626635Advanced Solid Tumors

DrugsMarlotamig·Trifluridine/Tipiracil·Cemiplimab·Bevacizumab

Regeneron Pharmaceuticals

Phase 1/2

548

Sant Cugat del Vallès, Pozuelo de Alarcón, Barcelona, Madrid, Valencia

2020-12-21

Active, closed

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer

DrugsAvutometinib (VS-6766) and defactinib·Avutometinib·Lumakras

Verastem, Inc.

Phase 2

225

Barcelona, Córdoba, Madrid, Valencia

2020-12-21

Recruiting

FS222 First in Human Study in Patients With Advanced Malignancies

NCT04740424Advanced Cancer, Metastatic Cancer

invoX Pharma Limited

Phase 1

260

Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville, Valencia

2020-12-14

Active, closed

Atrasentan in Patients With IgA Nephropathy

NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy

DrugsAtrasentan·Zigakibart

Novartis Pharmaceuticals

Phase 3

404

Barcelona, Madrid, Sagunto, Seville, Valencia

2020-12-11

Active, closed

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497IgG4 Related Disease

DrugInebilizumab

Amgen

Phase 3

135

Barcelona, Madrid, Valencia

2020-12-04

Active, closed

Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

NCT04463641Heart Failure, Cardiac Resynchronization Therapy

MicroPort CRM

Not applicable

Alicante, Valencia, Vigo

2020-12-03

Active, closed

Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)

NCT05649384Acute Chest Pain, NSTEMI - Non-ST Segment Elevation MI

University Hospital, Basel, Switzerland

Not applicable

64,374

Barcelona, Madrid, Valencia

2020-12-01

Active, closed

"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"

NCT05304754High-risk Leukemias

Instituto de Investigación Hospital Universitario La Paz

Phase 1/2

Santiago de Compostela, Oviedo, Barcelona, Madrid, Málaga, Murcia, Seville, Valencia

2020-11-30

Active, closed

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326Chronic Migraine

DrugGalcanezumab

Eli Lilly and Company

Phase 3

312

Barcelona, Seville, Valencia, Valladolid

2020-11-25

Active, closed

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax

Genmab

Phase 1/2

194

Barcelona, Coaña, Madrid, Seville, Valencia

2020-11-25

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/valencia?page=2

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,215 of those studies with a site in Valencia.

How many clinical trials are recruiting in Valencia?

621 of the 1,215 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 43 have not yet opened recruitment, 517 are active but closed to new participants, and 34 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.